Combination therapy with daclatasvir and asunaprevir for dialysis patients infected with hepatitis C virus

作     者：Ken Sato Yuichi Yamazaki Tatsuya Ohyama Takeshi Kobayashi Norio Horiguchi Satoru Kakizaki Motoyasu Kusano Masanobu Yamada 

作者机构：Department of Medicine and Molecular Science Gunma University Graduate School of Medicine Department of Gastroenterology Heisei Hidaka Clinic Department of Endoscopy and Endoscopic Surgery Gunma University Hospital 

出 版 物：《World Journal of Clinical Cases》 (世界临床病例杂志)

年 卷 期：2016年第4卷第3期

页      面：88-93页

核心收录：

学科分类：0831[工学-生物医学工程（可授工学、理学、医学学位）] 1004[医学-公共卫生与预防医学(可授医学、理学学位)] 1002[医学-临床医学] 08[工学] 100401[医学-流行病与卫生统计学] 10[医学] 

主　　题：Hepatitis C Oral drug Daclatasvir Asunaprevir Dialysis 

摘      要：The standard antiviral therapy for dialysis patients infected with hepatitis C virus(HCV) is(pegylated) interferon monotherapy, but its efficacy is insufficient. Oral direct-acting antiviral agents(DAAs) have recently been developed for chronic hepatitis C patients. However, some DAAs have contraindications for chronic renal failure(CRF). Daclatasvir and asunaprevir are metabolized largely in the liver and are not contraindicated in CRF. Combination therapy with daclatasvir and asunaprevir was used for 4 dialysis patients infected with genotype 1b HCV. One patient had viral breakthrough, and the 3 others had sustained virological response 12. One patient was admitted for heart failure and percutaneous coronary intervention due to concomitant ischemic disease. Heart failure was unlikely to be caused by the combination therapy, as it was probably due to water overload. The patient continued to receive the combination therapy after the remission of the heart failure. The combination therapy was well tolerated in the other patients.